Cargando…
Chronological Liquid Biopsy Reveals the Impact of Platinum-Based Chemotherapy on a Prostate Cancer Patient’s CDK12 Mutation: A Case Report
CDK12 (Cyclin-Dependent Kinase 12)-mutated prostate cancer patients often respond badly to current therapies. Immunotherapy and platinum-based chemotherapy are recommended based on the molecular features of CDK12-mutated tumors, but the reported patient outcomes are still unsatisfying. Here we repor...
Autores principales: | Zhu, Sha, Bao, Yige, Zheng, Linmao, Zhao, Jinge, Chen, Yuntian, Huang, Rui, Sun, Guangxi, Zhao, Fengnian, Zhang, Xingming, Liang, Jiayu, Chen, Junru, Wang, Zhipeng, Ni, Yuchao, Chen, Ni, Shen, Pengfei, Zeng, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9447454/ https://www.ncbi.nlm.nih.gov/pubmed/36082136 http://dx.doi.org/10.2147/OTT.S377638 |
Ejemplares similares
-
Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients
por: ZHU, SHA, et al.
Publicado: (2023) -
Retraction to the prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2023) -
The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2023) -
Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis
por: Chen, Junru, et al.
Publicado: (2020) -
Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Zhu, Sha, et al.
Publicado: (2022)